https://www.selleckchem.com/pr....oducts/sp-600125.htm
However, double negative expression of both markers was found only in 24% of the B-NHL patients. Conclusion CD160 with CD200 can be used as additional diagnostic markers to the available routine panel to differentiate between B-CLL and other non-specified B-NHL patients. Copyright © International Journal of Hematology-Oncology and Stem Cell Research Tehran University of Medical Sciences.Background Thalassemia as a chronic disease could affect different aspects of a patient's life. On the other hand, when encountering the symptom
Like
Comment
Share
